A new therapeutic avenue for management of neurological disorders.
Bacterial interventions focused to repair the disrupted gut microbiota have not been impressive. Successful microbiome therapies require a holistic approach addressing the dysbiosis but also other important hallmarks of the disease.
ImmuneBiotech is developing ImmuneBiotics™ – a new and multi-targeting probiotic category – focused on achieving a healthy balance between the microbiome, the immune system, and the intestinal barrier with a pharmaceutical precision.
Using a diverse collection of lactobacilli strains and advanced selection strategies, company´s first probiotic food supplement GutMagnific®- designed to address the underlying causes of IBS – has recently been launched. The scientific rational, translational success and importance of the choice of manufacturer ensuring the highest quality of the consumer product will be discussed in this presentation.
